Oruka Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed July 1, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 52/100
What the filing says
On July 1, 2026, Fairmount Healthcare Fund II L.P. converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of common stock at no cash consideration, then immediately sold all 3,553,410 newly converted shares in a block trade at $84.43/share for ~$299.9M. This represents a partial exit by a major 19.47% shareholder (Fairmount Funds Management LLC and affiliates combined), reducing their equity stake and generating substantial proceeds.
Why this rating
Block sale (~$300M) is 81% of company's $371.5M market cap—material in absolute terms. However, structured as conversion-and-immediate-sale of pre-existing Series B holdings, not dilutive new issuance. No change to capital structure, earnings, or operations. Signals shareholder confidence (conversion) but also partial exit. Modest negative (supply); modest positive (no capital raise needed). Net neutral.
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.